These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33400854)

  • 1. Discovery of an Allosteric Ligand Binding Site in SMYD3 Lysine Methyltransferase.
    Talibov VO; Fabini E; FitzGerald EA; Tedesco D; Cederfeldt D; Talu MJ; Rachman MM; Mihalic F; Manoni E; Naldi M; Sanese P; Forte G; Lepore Signorile M; Barril X; Simone C; Bartolini M; Dobritzsch D; Del Rio A; Danielson UH
    Chembiochem; 2021 May; 22(9):1597-1608. PubMed ID: 33400854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus NS5A protein interacts with lysine methyltransferase SET and MYND domain-containing 3 and induces activator protein 1 activation.
    Chen M; Gan X; Yoshino K; Kitakawa M; Shoji I; Deng L; Hotta H
    Microbiol Immunol; 2016 Jun; 60(6):407-17. PubMed ID: 27080060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-terminal domain of SMYD3 serves as a unique HSP90-regulated motif in oncogenesis.
    Brown MA; Foreman K; Harriss J; Das C; Zhu L; Edwards M; Shaaban S; Tucker H
    Oncotarget; 2015 Feb; 6(6):4005-19. PubMed ID: 25738358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Smyd3 open & closed lock mechanism for substrate recruitment: The hinge motion of C-terminal domain inferred from μ-second molecular dynamics simulations.
    Chandramouli B; Silvestri V; Scarno M; Ottini L; Chillemi G
    Biochim Biophys Acta; 2016 Jul; 1860(7):1466-74. PubMed ID: 27085704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unveiling the Biochemistry of the Epigenetic Regulator SMYD3.
    Fabini E; Talibov VO; Mihalic F; Naldi M; Bartolini M; Bertucci C; Del Rio A; Danielson UH
    Biochemistry; 2019 Sep; 58(35):3634-3645. PubMed ID: 31389685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.
    Hamamoto R; Furukawa Y; Morita M; Iimura Y; Silva FP; Li M; Yagyu R; Nakamura Y
    Nat Cell Biol; 2004 Aug; 6(8):731-40. PubMed ID: 15235609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets.
    Van Aller GS; Graves AP; Elkins PA; Bonnette WG; McDevitt PJ; Zappacosta F; Annan RS; Dean TW; Su DS; Carpenter CL; Mohammad HP; Kruger RG
    Structure; 2016 May; 24(5):774-781. PubMed ID: 27066749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of the Conformational Change of the Protein Methyltransferase SMYD3: A Molecular Dynamics Simulation Study.
    Sun J; Li Z; Yang N
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening.
    Gradl S; Steuber H; Weiske J; Szewczyk MM; Schmees N; Siegel S; Stoeckigt D; Christ CD; Li F; Organ S; Abbey M; Kennedy S; Chau I; Trush V; Barsyte-Lovejoy D; Brown PJ; Vedadi M; Arrowsmith C; Husemann M; Badock V; Bauser M; Haegebarth A; Hartung IV; Stresemann C
    SLAS Discov; 2021 Sep; 26(8):947-960. PubMed ID: 34154424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and biochemical studies of human lysine methyltransferase Smyd3 reveal the important functional roles of its post-SET and TPR domains and the regulation of its activity by DNA binding.
    Xu S; Wu J; Sun B; Zhong C; Ding J
    Nucleic Acids Res; 2011 May; 39(10):4438-49. PubMed ID: 21266482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic analyses of the SMYD family interactomes identify HSP90 as a novel target for SMYD2.
    Abu-Farha M; Lanouette S; Elisma F; Tremblay V; Butson J; Figeys D; Couture JF
    J Mol Cell Biol; 2011 Oct; 3(5):301-8. PubMed ID: 22028380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of the hepatitis B virus X protein with the lysine methyltransferase SET and MYND domain-containing 3 induces activator protein 1 activation.
    Hayashi M; Deng L; Chen M; Gan X; Shinozaki K; Shoji I; Hotta H
    Microbiol Immunol; 2016 Jan; 60(1):17-25. PubMed ID: 26616333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization.
    Yoshioka Y; Suzuki T; Matsuo Y; Tsurita G; Watanabe T; Dohmae N; Nakamura Y; Hamamoto R
    Cancer Med; 2017 Jul; 6(7):1665-1672. PubMed ID: 28639750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Basis for Substrate Preference of SMYD3, a SET Domain-containing Protein Lysine Methyltransferase.
    Fu W; Liu N; Qiao Q; Wang M; Min J; Zhu B; Xu RM; Yang N
    J Biol Chem; 2016 Apr; 291(17):9173-80. PubMed ID: 26929412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of the 4-aminopiperidine-based compound EM127 for the site-specific covalent inhibition of SMYD3.
    Parenti MD; Naldi M; Manoni E; Fabini E; Cederfelt D; Talibov VO; Gressani V; Guven U; Grossi V; Fasano C; Sanese P; De Marco K; Shtil AA; Kurkin AV; Altieri A; Danielson UH; Caretti G; Simone C; Varchi G; Bartolini M; Del Rio A
    Eur J Med Chem; 2022 Dec; 243():114683. PubMed ID: 36116234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription.
    Kim H; Heo K; Kim JH; Kim K; Choi J; An W
    J Biol Chem; 2009 Jul; 284(30):19867-77. PubMed ID: 19509295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone lysine methyltransferase SMYD3 promotes oral squamous cell carcinoma tumorigenesis via H3K4me3-mediated HMGA2 transcription.
    Yang Z; Liu F; Li Z; Liu N; Yao X; Zhou Y; Zhang L; Jiang P; Liu H; Kong L; Lang C; Xu X; Jia J; Nakajima T; Gu W; Zheng L; Zhang Z
    Clin Epigenetics; 2023 May; 15(1):92. PubMed ID: 37237385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells.
    Luo XG; Zou JN; Wang SZ; Zhang TC; Xi T
    IUBMB Life; 2010 Mar; 62(3):194-9. PubMed ID: 20039369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand Binding, Unbinding, and Allosteric Effects: Deciphering Small-Molecule Modulation of HSP90.
    D'Annessa I; Raniolo S; Limongelli V; Di Marino D; Colombo G
    J Chem Theory Comput; 2019 Nov; 15(11):6368-6381. PubMed ID: 31538783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Silico/In Vitro Hit-to-Lead Methodology Yields SMYD3 Inhibitor That Eliminates Unrestrained Proliferation of Breast Carcinoma Cells.
    Alshiraihi IM; Jarrell DK; Arhouma Z; Hassell KN; Montgomery J; Padilla A; Ibrahim HM; Crans DC; Kato TA; Brown MA
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.